Fig. 3

The Treg-promoting effect of PPARγ agonists is dampened by knocking down CD36/CPT1. a, b The naïve CD4⁺ T cells were transfected with siCD36 or siCPT1, and the protein levels of CD36 (a) and CPT1 (b) were detected by western blotting. c, d The naïve CD4⁺ T cells were transfected with siCD36 or siCPT1, and treated with anti-CD3/CD28 in the presence or absence of TGF-β (5 ng/mL), rosiglitazone (30 μM), 15d-PGJ2 (10 μM) as well as morin (30 μM) for 72 h. The frequency of CD4⁺Foxp3⁺ T cells was examined by flow cytometry (c) and the mRNA expression level of Foxp3 was measured by Q-PCR (d). Data were presented as the means ± S.E.M. of three independent experiments (n = 3). ^#P < 0.05, ^##P < 0.01 versus control group; **P < 0.01 versus TGF-β group (model group); ^$P < 0.05, ^$$P < 0.01 versus rosiglitazone group; ^&P < 0.05, ^&&P < 0.01 versus 15d-PGJ2 group; ^†P < 0.05 versus morin group